首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

2126362

醫院感染診斷市場：策略性洞察與預測（2026-2035 年）

Hospital-Acquired Infection Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月05日 | 出版商:

Knowledge Sourcing Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計醫院感染診斷市場將從 2026 年的 86.2 億美元成長到 2035 年的 188.8 億美元，複合年成長率為 9.1%。

由於抗生素抗藥性威脅日益加劇、醫療相關感染負擔不斷加重以及快速鑑定病原體以支持標靶治療的需求，醫院感染診斷市場正經歷顯著的變革。這一市場演變的特點是從傳統培養方法轉向整合分子診斷、自動化微生物工作流程和多項目症候群檢測平台的模式轉移。醫療系統正在擴展其診斷能力，透過早期識別病原體、區分抗藥性菌株並在併發症進展前支持標靶抗生素治療，來減少對經驗性治療的依賴。分子診斷、質譜和數位監測系統的整合能夠實現更快、更全面、更具可操作性的感染檢測。隨著醫院持續影響相當大比例的住院患者，醫院正在擴大感染監測項目，對檢查室自動化和分子診斷產生了持續的需求。監管機構正在加強感染預防和報告框架，並鼓勵醫療機構實施標準化的診斷方案和監測系統。隨著市場對多分子檢測、即時檢測技術和人工智慧驅動的檢測工作流程的大量投資，HAI 診斷正在成為病患安全、合理使用抗生素和醫院品質績效的關鍵要素。

市場促進因素

醫療相關感染疾病(HAI) 負擔日益惡化是 HAI 診斷市場的主要驅動力。由於侵入性醫療操作、加護病房入院以及患者群體老化等因素導致感染風險不斷增加，院內感染仍然是一個持續存在的挑戰。醫療機構正在擴展其診斷能力，以縮短從臨床懷疑到病原體鑑定的時間。傳統的微生物檢測通常需要較長的培養時間，因此對快速分子診斷技術的需求不斷成長，以加速治療啟動。診斷設備製造商正在開發能夠同時檢測多種病原體的多重檢測方法。更快的診斷速度有助於改善感染控制決策，並支持合理的抗菌藥物使用方案，從而減少不合理使用抗生素，最終推動 HAI 診斷市場的持續成長。抗生素抗藥性的加劇進一步加速了市場成長，因為對快速抗藥性檢測的需求日益成長。抗生素抗藥性的增加使醫院的感染控制更加複雜，因為抗藥性病原體通常需要特定的治療策略。醫療機構正在採用先進的診斷平台，這些平台能夠在檢測病原體的同時快速識別抗藥性標記物。識別延遲不僅會降低治療效果，還會因住院時間延長而增加醫療成本。診斷技術的創新正擴展到症候群特異性檢測和抗藥性基因檢測，從而支持精準選擇抗生素。早期識別能夠改善患者預後，並加強整個醫療系統的抗生素使用方案。隨著感染預防方案的擴展，對監測和自動化報告的需求也不斷成長。在醫療品質架構中，感染預防作為一項可衡量的績效指標正日益受到重視。醫院正在加強其監測系統，以符合國家報告要求和認證標準。由於人工監測限制了疫情爆發期間的及時干預，因此對自動化檢查室報告和整合診斷系統的需求日益成長。診斷設備供應商正在其產品中整合連接功能，以實現向感染預防團隊的即時報告。快速分子診斷的日益普及正在改善臨床決策和檢查室效率。臨床決策依賴檢查室及時提供的明確診斷，因為治療延遲會導致發病率增加和醫療成本上升。醫療檢查室正在從單一標靶檢測轉向多分子診斷平台，這種平台可以在一次檢查週期內識別多種病原體。

市場限制因素

分子診斷平台和檢查室自動化所需的大量資本投入限制了小規模、資源有限的醫療機構採用這些技術。沉重的經濟負擔是小規模機構的一大障礙。不同醫療體系的報銷標準各異，降低了醫院以先進分子診斷取代傳統微生物工作流程的經濟獎勵。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。儘管臨床需求不斷成長，但熟練技術人員的短缺和複雜的檢驗要求阻礙了先進診斷技術的應用。缺乏訓練有素的人員限制了先進診斷技術的擴充性。不同地區法規的複雜性也給尋求將新型診斷解決方案商業化的製造商帶來了合規負擔。

對感染疾病技術和類型的深入了解

技術發展趨勢的特徵是整合分子診斷和自動化微生物工作流程的重要性日益凸顯。隨著醫療服務提供者需要在臨床上適宜的時限內獲得可操作的結果，分子診斷正發揮越來越重要的作用。檢查室正在擴展其PCR和多重檢測能力，以同時識別病原體和抗藥性標記。傳統的培養為基礎的微生物檢測仍然是支持抗菌藥物敏感性評估和流行病學調查的重要參考方法。免疫檢測繼續應用於優先考慮快速篩檢和成本效益的特定領域。隨著微生物鑑定工作流程對通量和分析精確度的要求不斷提高，基於質譜的診斷方法的應用也日益增加。細分市場分析表明，血流感染疾病的診斷需求顯著更高，因為延遲識別會增加死亡風險並延長住院時間。醫院正在優先採用快速分子診斷和自動化血液培養技術，以加速治療決策。手術部位感染疾病需要準確識別病原體，因為術後併發症會增加醫療資源消耗和再入院率。醫療機構正在加強對醫院獲得性肺炎、人工呼吸器相關性肺炎和導尿管相關尿道感染的監測。由於抗生素的使用會改變胃腸道微生物群並增加復發風險，困難梭狀桿菌感染疾病仍需採用專門的實驗室方法。檢查室檢測仍然是醫院的主要診斷方法，需要進行全面的病原體鑑定、藥物敏感性測試和監測報告。隨著醫療機構在不影響診斷品質的前提下追求更快的檢測結果，對自動化檢測系統的需求正在成長。在重症監護環境中，由於需要立即獲得臨床資訊以指南治療，床邊檢測的應用正在不斷擴展。隨著醫療系統中診斷數量的增加以及對快速決策需求的持續成長，隨著實驗室自動化技術的進步，人工智慧的整合變得越來越重要。人工智慧透過輔助影像分析、微生物鑑定和最佳化實驗室工作流程，正在幫助提高營運效率。

競爭格局與策略展望

競爭格局包括成熟的診斷和生命科學公司，以及專注於微生物學、分子檢測和自動化領域的供應商。羅氏在感染疾病診斷領域保持強大的市場地位。其分子檢測產品組合支援在醫院和檢查室環境中快速檢測病原體，並利用 cobas 平台提供高度擴充性的基於 PCR 的檢測解決方案，這些方案可以與現有的檢測工作流程整合。賽默飛世爾科技憑藉其廣泛的生命科學和診斷產品組合脫穎而出，該產品組合支持微生物學、分子檢測和檢查室自動化，並受益於儀器、試劑和檢查室服務之間的強大整合。生物梅里埃繼續佔據著重要的戰略地位，其經營模式的核心是微生物學和感染疾病診斷，並透過基於培養的系統、分子診斷和抗生素使用解決方案為醫院檢查室提供支援。 BD 透過將檢體管理、微生物診斷和檢查室自動化技術相結合而佔據獨特的市場地位。其 BD Kiestra 自動化平台支援標準化的工作流程，從而減少人工操作並提高處理能力。丹納赫透過其診斷業務（包括貝克曼庫爾特和Cefeid）進入市場，充分利用其在分子診斷、檢查室自動化和臨床工作流程最佳化方面的強大實力。雅培則憑藉其在診斷、檢查室系統和即時檢測方面的專業知識，滿足感染疾病檢測的需求。西門子醫療透過整合診斷、檢查室自動化和醫療技術解決方案脫穎而出。凱傑的分子診斷技術有助於快速檢測病原體和抗菌素抗藥性標記物，因此保持著重要的戰略地位。各公司都在透過在多分子檢測、即時檢測技術和人工智慧驅動的檢測工作流程方面的創新來拓展其產品系列。在感染疾病監測和合理使用抗菌藥物的需求推動下，診斷設備製造商與醫療系統之間的策略夥伴關係日益增多。地理擴張仍然是關鍵的策略重點，各公司正將目光投向快速成長的亞太地區和醫療基礎設施不斷完善的新興市場。

簡明結論

醫院感染（HAI）診斷市場預計將持續成長，這主要得益於感染負擔加重、抗生素抗藥性加劇以及診斷技術創新等因素的共同推動。從傳統培養方法向整合分子診斷和自動化平台的轉變，標誌著感染控制領域的根本性變革。儘管高成本、報銷機制差異以及勞動力短缺等挑戰依然存在，但對技術、自動化和夥伴關係的策略性投資正在為市場領導創造永續的競爭優勢。長期市場前景依然樂觀，醫院感染（HAI）診斷正發展成為保障病人安全和醫療品質的關鍵要素，有助於快速識別病原體、合理使用抗生素，並改善全球醫療系統中的患者預後。

本報告的主要益處

深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業部門進行詳細的市場洞察。
競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
實用建議：我們支援制定策略決策以開發新的收入來源。
適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

產業和市場洞察、機會評估、產品需求預測、打入市場策略、區域擴張、資本投資決策、監管分析、新產品開發和競爭情報。

調查範圍

歷史資料涵蓋 2021 年至 2024 年，基準年為 2025 年，預測期為 2026 年至 2035 年。
成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
競爭對手定位、策略、市場佔有率評估和貿易分析
細分市場和區域銷售成長及預測評估
公司簡介，包括策略、產品、財務狀況和主要發展動態。

按感染類型
- 血液感染疾病（BSI）
- 手術部位感染（SSI）
- 院內獲得性肺炎（HAP）和人工呼吸器相關性肺炎（VAP）
- 導尿管相關尿道感染（CAUTI）
- 困難梭狀桿菌感染疾病（CDI）
- 其他院內感染
透過診斷技術
- 分子診斷
- 免疫測量
- 微生物培養試驗
- 基於質譜的診斷
- 其他診斷技術
按測試類型
- 檢查室測試
- 即時檢測
依病原體類型
- 細菌病原體
- 病毒病原體
- 真菌病原體
- 多重抗藥性細菌（MDRO）
依樣本類型
- 血
- 尿
- 呼吸系統檢體
- 傷口和組織檢體
- 糞便檢體
- 其他檢體
最終用戶
- 醫院
- 臨床實驗室
- 參考實驗室
- 學術研究機構

第10章：醫院感染診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：醫院感染診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
澳洲
巴西
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
bioMerieux SA
Becton, Dickinson and Company
Danaher Corporation
Abbott Laboratories
Siemens Healthineers AG
Qiagen NV
Bio-Rad Laboratories, Inc.
Hologic, Inc.
Bruker Corporation
Revvity, Inc.
Cepheid
Seegene Inc.
Werfen SA

第14章：醫院感染診斷市場：商業預測分析

第15章：投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009073

The Hospital-Acquired Infection Diagnostics Market is anticipated to grow at a CAGR of 9.1% from USD 8.62 billion in 2026 to USD 18.88 billion in 2035.

The hospital-acquired infection diagnostics market is undergoing significant transformation driven by the escalating threat of antimicrobial resistance, the growing burden of healthcare-associated infections, and the imperative for rapid pathogen identification to support targeted therapy. The market's evolution is characterized by a paradigm shift from conventional culture-based methods toward integrated molecular diagnostics, automated microbiology workflows, and multiplex syndromic testing platforms. Healthcare systems are expanding diagnostic capabilities to identify pathogens earlier, distinguish resistant organisms, and support targeted antimicrobial therapy before complications progress, reducing reliance on empirical treatment. The convergence of molecular diagnostics, mass spectrometry, and digital surveillance systems is enabling faster, more comprehensive, and increasingly actionable infection detection. Hospitals are expanding infection surveillance programs because healthcare-associated infections continue affecting a substantial proportion of hospitalized patients, creating sustained demand for laboratory automation and molecular diagnostics. Regulatory agencies are strengthening infection prevention and reporting frameworks, encouraging healthcare facilities to adopt standardized diagnostic protocols and surveillance systems. The market is witnessing significant investment in multiplex molecular assays, point-of-care technologies, and AI-enabled laboratory workflows, positioning HAI diagnostics as a critical component of patient safety, antimicrobial stewardship, and hospital quality performance.

Market Drivers

The growing burden of healthcare-associated infections represents the primary driver for the HAI diagnostics market. Hospital-acquired infections remain a persistent challenge because invasive medical procedures, intensive care admissions, and aging patient populations continue increasing infection susceptibility. Healthcare providers are expanding diagnostic capacity to reduce delays between clinical suspicion and pathogen confirmation. Conventional microbiology often requires extended incubation periods, creating pressure for rapid molecular technologies that shorten treatment initiation. Diagnostic manufacturers are developing multiplex assays capable of detecting multiple pathogens simultaneously. Faster diagnosis improves infection control decisions while supporting antimicrobial stewardship programs that reduce inappropriate antibiotic utilization, resulting in sustained growth in HAI diagnostic utilization. Escalating antimicrobial resistance is further accelerating market growth through demand for rapid resistance detection. Antimicrobial resistance increases the complexity of hospital infection management because resistant pathogens frequently require organism-specific therapeutic strategies. Healthcare institutions are adopting advanced diagnostic platforms that rapidly identify resistance markers alongside pathogen detection. Delayed identification limits therapeutic effectiveness and increases healthcare costs through prolonged hospitalization. Diagnostic innovation is expanding toward syndromic panels and resistance gene detection to support precision antimicrobial selection. Earlier identification improves patient outcomes while strengthening antimicrobial stewardship programs across healthcare systems. The expansion of infection prevention programs is increasing demand for surveillance and automated reporting. Healthcare quality frameworks increasingly emphasize infection prevention as a measurable performance indicator. Hospitals are strengthening surveillance infrastructure to comply with national reporting requirements and accreditation standards. Manual surveillance limits timely intervention during outbreaks, creating demand for automated laboratory reporting and integrated diagnostic systems. Diagnostic vendors are incorporating connectivity features that enable real-time reporting to infection prevention teams. The increasing adoption of rapid molecular diagnostics is improving clinical decision-making and laboratory efficiency. Clinical decision-making depends on timely laboratory confirmation because delayed treatment increases morbidity and healthcare expenditure. Healthcare laboratories are replacing single-target assays with multiplex molecular platforms capable of identifying numerous pathogens during one testing cycle.

Market Restraints

High capital investment requirements for molecular diagnostic platforms and laboratory automation limit adoption among small and resource-constrained healthcare facilities. The significant financial commitment creates barriers for smaller institutions. Reimbursement variability across healthcare systems reduces financial incentives for hospitals to replace conventional microbiology workflows with advanced molecular diagnostics. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Skilled laboratory workforce shortages and complex validation requirements slow implementation of sophisticated diagnostic technologies despite increasing clinical demand. The shortage of trained personnel limits the scalability of advanced diagnostics. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Infection Type Insights

The technology landscape is characterized by the growing importance of integrated molecular diagnostics and automated microbiology workflows. Molecular diagnostics increasingly occupy a central role because healthcare providers require actionable results within clinically relevant timeframes. Laboratories are expanding PCR and multiplex testing capabilities to identify pathogens and resistance markers simultaneously. Conventional microbiology culture-based testing remains an essential reference method because it supports antimicrobial susceptibility assessment and epidemiological investigations. Immunoassays continue serving targeted applications where rapid screening and cost efficiency remain priorities. Mass spectrometry-based diagnostics are gaining adoption because microbial identification workflows require higher throughput and greater analytical precision. The segment analysis reveals that bloodstream infections generate significant diagnostic demand because delayed identification increases mortality risk and extends hospitalization. Hospitals are prioritizing rapid molecular assays and automated blood culture technologies to accelerate therapeutic decisions. Surgical site infections require precise pathogen characterization because post-operative complications increase healthcare utilization and readmission rates. Healthcare providers are strengthening surveillance programs for hospital-acquired pneumonia, ventilator-associated pneumonia, and catheter-associated urinary tract infections as intensive care utilization remains high. Clostridioides difficile infections continue requiring specialized testing approaches because antimicrobial exposure alters gastrointestinal microbiota and increases recurrence risk. Laboratory-based testing remains the dominant diagnostic approach because hospitals require comprehensive pathogen identification, susceptibility testing, and surveillance reporting. Demand is shifting toward automated laboratory systems as healthcare facilities seek faster turnaround times without compromising diagnostic quality. Point-of-care testing is expanding because critical care environments require immediate clinical information to guide treatment initiation. The integration of AI is becoming increasingly important because laboratory automation continues advancing as healthcare systems require faster interpretation of growing diagnostic volumes. AI is supporting image analysis, microbial identification, and laboratory workflow optimization to improve operational efficiency.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized microbiology, molecular testing, and automation providers. Roche maintains a strong position in infectious disease diagnostics because its molecular testing portfolio supports rapid pathogen detection across hospital and laboratory environments, leveraging its cobas platform to provide scalable PCR-based testing solutions that integrate with established laboratory workflows. Thermo Fisher Scientific differentiates itself through a broad life sciences and diagnostics portfolio that supports microbiology, molecular testing, and laboratory automation, benefiting from strong integration across instruments, reagents, and laboratory services. bioMerieux remains strategically important because microbiology and infectious disease diagnostics form the core of its business model, supporting hospital laboratories through culture-based systems, molecular diagnostics, and antimicrobial stewardship solutions. BD occupies a distinctive position because it combines specimen management, microbiology diagnostics, and laboratory automation technologies, with its BD Kiestra automation platform supporting standardized workflows that reduce manual intervention and improve throughput. Danaher participates in the market through its diagnostic businesses, including Beckman Coulter and Cepheid, benefiting from strong capabilities in molecular diagnostics, laboratory automation, and clinical workflow optimization. Abbott leverages expertise in diagnostics, laboratory systems, and point-of-care testing to address infectious disease detection requirements. Siemens Healthineers differentiates itself through integration of diagnostics, laboratory automation, and healthcare technology solutions. QIAGEN maintains strategic relevance because its molecular diagnostic technologies support rapid detection of infectious agents and antimicrobial resistance markers. Companies are pursuing product portfolio expansion through innovation in multiplex molecular assays, point-of-care technologies, and AI-enabled laboratory workflows. Strategic collaborations between diagnostic manufacturers and healthcare systems are increasing, driven by the need for infection surveillance and antimicrobial stewardship. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The hospital-acquired infection diagnostics market is positioned for sustained growth driven by the convergence of infection burden, antimicrobial resistance, and diagnostic innovation. The transition from conventional culture-based methods toward integrated molecular and automated platforms represents a fundamental shift in infection management. While challenges related to high costs, reimbursement variability, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with HAI diagnostics evolving into a critical component of patient safety and healthcare quality, supporting rapid pathogen identification, antimicrobial stewardship, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Hospital-Acquired Infection Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Hospital-Acquired Infection Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Epidemiology and Disease Burden Analysis
3.8 Incidence of Major Hospital-Acquired Infections
3.9 Diagnosed Patient Population Analysis
3.10 Testing Volume Analysis
3.11 Antimicrobial Resistance and Diagnostic Demand Assessment
3.12 Clinical Diagnostic Pathway Analysis

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Molecular Diagnostics Innovation
6.3 Rapid Point-of-Care Testing Developments
6.4 Clinical Trial Analysis
6.5 Pipeline Analysis of Diagnostic Assays and Platforms
6.6 Artificial Intelligence and Machine Learning Integration
6.7 Digital Health Integration and Hospital Surveillance Systems
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Hospital-Acquired Infection Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Testing Methodology
8.3 Analysis by Biomarker and Pathogen Detection Approach
8.4 Analysis by Sample Type
8.5 Analysis by Clinical Application
8.6 Analysis by Diagnostic Turnaround Time

9. Hospital-Acquired Infection Diagnostics Market Segment Analysis (2021-2035)

9.1 By Infection Type
- 9.1.1 Bloodstream Infections (BSIs)
- 9.1.2 Surgical Site Infections (SSIs)
- 9.1.3 Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP)
- 9.1.4 Catheter-Associated Urinary Tract Infections (CAUTIs)
- 9.1.5 Clostridioides difficile Infections (CDI)
- 9.1.6 Other Hospital-Acquired Infections
9.2 By Diagnostic Technology
- 9.2.1 Molecular Diagnostics
- 9.2.2 Immunoassays
- 9.2.3 Microbiology Culture-Based Testing
- 9.2.4 Mass Spectrometry-Based Diagnostics
- 9.2.5 Other Diagnostic Technologies
9.3 By Test Type
- 9.3.1 Laboratory-Based Testing
- 9.3.2 Point-of-Care Testing
9.4 By Pathogen Type
- 9.4.1 Bacterial Pathogens
- 9.4.2 Viral Pathogens
- 9.4.3 Fungal Pathogens
- 9.4.4 Multidrug-Resistant Organisms (MDROs)
9.5 By Sample Type
- 9.5.1 Blood
- 9.5.2 Urine
- 9.5.3 Respiratory Samples
- 9.5.4 Wound and Tissue Samples
- 9.5.5 Stool Samples
- 9.5.6 Other Samples
9.6 By End User
- 9.6.1 Hospitals
- 9.6.2 Clinical Laboratories
- 9.6.3 Reference Laboratories
- 9.6.4 Academic and Research Institutes